BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.
BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 23, 2019 | Series D | $299.20M | 3 | Kohlberg Kravis Roberts | — | Detail |
Sep 13, 2017 | Series C | $135M | 2 | Kohlberg Kravis Roberts | — | Detail |
May 1, 2017 | Series B | $33.10M | 1 | Kohlberg Kravis Roberts | — | Detail |
Mar 1, 2016 | Series B | $6.90M | 1 | Kohlberg Kravis Roberts | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Kohlberg Kravis Roberts | Yes | Series D |
Sequoia Capital | — | Series D |
Hercules Capital | — | Series D |
Janus Fund | — | Series C |